Hot topics | Coronavirus pandemic

Is Omicronn so enticed by 2020? Here's why it shouldn't?

Is Omicronn so enticed by 2020? Here's why it shouldn't?

A new SARS-CoV-2 virus variant is rattling the globe, prompting and some scientists to figure out how dangerous the new strain, called Omicron, might be.

The World Health Organization on Monday warned of very high risk from Omicron, as a slew of concerns about its transmissibility and severity remain under investigation. Health experts are cautioning against any panic until the scientific community learns more about those concerns, as well as whether the variant evades the immune response from existing vaccinations or a prior COVID-19 infection.

Given the amount of uncertainty, it might appear like the spring of 2020 will be over again. (Remember the first time you heard the words social distancing?)

However, there are several reasons why the pandemic landscape today is extremely different: the majority of people have received COVID surges before, from doctors to public health officials to employers, and the general public (most of them, anyway) knows how to wear a mask.

Here's a breakdown of everything that has changed.

People have access to a variety of COVID-19 vaccinations this summer, which have been proven to provide protection against severe diseases of the disease. Over the summer, the three US vaccine manufacturings Johnson & Johnson, Pfizer-BioNTech, and Moderna discovered encouraging data about their ability to protect individuals.

On Monday, Dr. Anthony Fauci, the country's top infectious disease expert, stated that people should not be freaking out over Omicron, and he urged the country to do the things we know work, which include being vaccinated or receiving a booster shot.

Even if Omicron is more transmissible than other COVID-19 strains, local authorities should be better equipped to respond in a way that doesn't necessitate.

During a press conference on Monday, President Joe Biden stated, If people are vaccinated and wearing their mask, there is no need for a lockdown.

Nonetheless, there is an ongoing worry that the Omicron variant, which contains more than 30 mutations in the spike protein, may escape the current vaccinations' immune protection as well as prior infection. Moderna chief executive Stephane Bancel told CNBC's Squawk Box that he expects a loss of vaccination efficacy to prevent disease.

All three US vaccine manufacturers, such as Johnson & Johnson, Pfizer-BioNTech, and Moderna, claim that their vaccinations adequately protect against the disease, but it may take a few weeks before they have that data in hand.

Meanwhile, some drugmakers are accelerating the development of Omicron-specific vaccine candidates. It's unclear if tweaked vaccines are required, but both and have stated that they may produce another version by early next year. Johnson & Johnson is also pursuing a potential vaccination targeting Omicron.

That's a far faster time than the effort to obtain the first COVID-19 vaccinations approved last year. The US Food and Drug Administration has stated that booster doses will be sent through major clinical trails in order to speed up their development and ability to target emerging variants.

According to chief executive Albert Bourla, a promising COVID-19 treatment pill from Pfizer may be beneficial against the Omicron variant.

So that gives me a tremendous level of confidence that the treatment will not be affected, Bourla stated on Monday. So that gives me a very high level of confidence that the treatment will not be affected.

Paxloid, a pill that has yet to be authorized by the FDA for emergency use, has been proven to reduce the risks of hospitalization and death by almost 90 percent when taken shortly before the onset of symptoms.

Recent Merck studies on the competing COVID-19 pill show that the treatment might not function as well as previously planned. It has just a 30% chance of warding off mild to moderate disease. The firm has not disclosed its effectiveness against the Omicron variant.

Diti Kohli can be reached at her on Twitter. Anissa Gardizy can be reached at her on Twitter. Follow her on Twitter.

You may also like: